International Webinar - Eradicate hep C in OST setting
Wednesday 13th September 2017

NSW/TAS/ACT/QLD/VIC: 7.30pm - 9.00pm
SA/NT: 7.00pm - 8.30pm
WA: 5.30pm - 7.00pm

Learning Objectives

After attending this webinar, you should be able to:
  • Identify barriers and drivers of HCV treatment in the drug and alcohol setting
  • Implement practical steps to simplify the HCV treatment process
  • Understand the available HCV treatment options and considerations for optimising individualised treatment.

Professor Robert Gish
Prof. Gish is a world-renowned hepatologist and is a consulting clinical professor of Medicine at Stanford University (Consultant), Senior Medical Director at Medical Center in Phoenix, and Medical Director at La Maestra in San Diego. He is also part of the leadership groups of the National Viral Hepatitis Roundtable, Hepatitis B Foundation and Vietnam Viral Hepatitis Alliance, in addition to running his own consulting firm.

Professor Paul Haber
Paul Haber is a physician specializing in addiction medicine and gastroenterology / hepatology. He is Clinical Director for Drug Health Services for the Sydney Local Health District and has been a consultant at Royal Prince Alfred Hospital since 1998. He is a Foundation Fellow and past President of the Royal Australasian College of Physicians Chapter of Addiction Medicine, and a conjoint Professor at the University of Sydney. His research interests focus on health problems related to substance use particularly liver disease.

 If you have previously registered for this event, please login below (The password can be found on the invitation):

Registration is required to attend this event. Please register now.
First Name*
Last Name*
Telephone Number
Practice / Hospital Name*
(The password can be found on the invitation)

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.
Once you have registered, we will send an email with the link and a password for the night.
 I agree to receive phone calls from MSD about events, educational activities, services, products or other information connected with MSD. Information may include updates on education, services, events and products provided by MSD (please note some material may be promotional in nature).
 I agree to receive information and electronic messages from MSD including updates on education, services, events and products provided by MSD (please note some material may be promotional in nature).
 I have read and accept the Privacy Collection and Terms of Use below.*
Mobile Phone Number – enter if you wish to receive SMS reminders for this event*
*Unless otherwise stated, your mobile number will only be used for SMS reminders relating to this specific event and will not subsequently be captured or used for any other purpose.
Please enable Cookies in your browser before registering for the webcast.
*Denotes required.

References: 1. Hepatitis Australia. Media release, July 28 2016. 2. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2015.
Privacy Collection Statement: Merck Sharp & Dohme (Australia) Pty Limited (“MSD”) will collect, record and use your personal information for the purposes of conducting the above event and providing information about MSD products and activities including by way of electronic messages. if you choose not to provide us with your personal information, we may not be able to fulfill these purposes. We will keep your personal information for only as long as is necessary to carry out the purposes described above (unless we are required or permitted by law to hold the information for a longer period). We may disclose your personal information to organisations who assist us and our affiliated companies (which may be located in other countries including United States, United Kingdom, China and India. If you would like to know more about our privacy policy, including how to access and seek correction of the personal information MSD holds about you, how to complain about a breach of the Australian Privacy Principles, and how MSD handles such complaints, please go to http://www.msd-australia.com.au/aboutus/how-we-operate/pages/privacy.aspx or contact our Privacy Officer at Locked Bag 2234, North Ryde, NSW 1670, T +61 2 8988 8000, E PrivacyOfficeANZ@merck.com.

By supplying your contact details, you also consent for MSD to contact you for follow-up information if a safety report is identified.

Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ, USA. All rights reserved. Level 1, Building A, 26 Talavera Rd, Macquarie Park, NSW 2113 Australia. INFC-1215744-0003. INFC-1224952-0001. First issued August 2017.

Terms of Use | Privacy Policy | Contact Us